Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vertex PharmaceuticalsMEX:VRTX 91 EV-to-OCF is 27.48 as of Sep. 14, 2026, which is 2% above its 10-year median of 26.84. GuruFocus rates MEX:VRTX with a GF Score™ of 91/100 and a GF Value™ of MXN8,957.40 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,406 Biotechnology companies, Vertex Pharmaceuticals ranks worse than 91.39% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Vertex Pharmaceuticals's Enterprise Value is MXN2,119,649 Mil.
Vertex Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was MXN77,129 Mil. Therefore, Vertex Pharmaceuticals's EV-to-OCF for today is 27.48.
The historical rank and industry rank for Vertex Pharmaceuticals's EV-to-OCF or its related term are showing as below:
MEX:VRTX'
s EV-to-OCF Range Over the Past 10 Years
Min: -3136.2 Med: 26.84 Max: 185.95
Current: 29.06
During the past 13 years, the highest EV-to-OCF of Vertex Pharmaceuticals was 185.95. The lowest was -3136.20. And the median was 26.84.
MEX:VRTX's EV-to-OCF is ranked worse than 91.39% of 1406
companies
in the Biotechnology industry
Industry Median: -3.38
vs MEX:VRTX: 29.06
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vertex Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Vertex Pharmaceuticals's share price for today is MXN8776.36.
Vertex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN307.979.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VRTX vs REGN, MRNA, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's EV-to-OCF falls into.
Vertex Pharmaceuticals's current Enterprise Value is MXN2,119,649 Mil.
Vertex Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN77,129 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (MEX:VRTX) has a EV-to-OCF of 27.48 as of Sep. 14, 2026. This is near median its historical median of 26.84. According to the industry distribution chart, Vertex Pharmaceuticals ranks #1285 out of 1406 companies in the Biotechnology industry, placing it in the top 91.4%.
Is Vertex Pharmaceuticals' EV-to-OCF too high?
Vertex Pharmaceuticals' current EV-to-OCF of 27.48 is near median its 10-year median of 26.84. Based on the distribution chart, Vertex Pharmaceuticals ranks #1285 out of 1406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' EV-to-OCF compare to REGN and MRNA?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #1285 out of 1406 companies for EV-to-OCF. This places Vertex Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Vertex Pharmaceuticals's current EV-to-OCF is 27.48, which is near median its own 10-year median of 26.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,957.40, compared to a current price of MXN8,776.36 — trading 2% below its estimated fair value. The current EV-to-OCF is 27.48, which is near median its 10-year median of 26.84. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current EV-to-OCF is 27.48 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN8,776.36 is trading 2% below its estimated GF Value™ of MXN8,957.40.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
EV-to-OCF: 27.48 (near median its 10-year median of 26.84)
GF Value™: MXN8,957.40 vs. price of MXN8,776.36 (2% below fair value)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score
Get the complete analysis for MEX:VRTX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
